CU24335B1 - Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer - Google Patents

Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer

Info

Publication number
CU24335B1
CU24335B1 CUP2014000109A CU20140109A CU24335B1 CU 24335 B1 CU24335 B1 CU 24335B1 CU P2014000109 A CUP2014000109 A CU P2014000109A CU 20140109 A CU20140109 A CU 20140109A CU 24335 B1 CU24335 B1 CU 24335B1
Authority
CU
Cuba
Prior art keywords
cancer
mek kinase
treatment
useful
piridopirimidinas
Prior art date
Application number
CUP2014000109A
Other languages
English (en)
Spanish (es)
Other versions
CU20140109A7 (es
Inventor
Rakesh Kumar Banerjee
Bhavesh Dave
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Rajender Kumar Kamboj
Abhijit Datta Khoje
Venkata P Palle
Samiron Phukan
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24335(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20140109A7 publication Critical patent/CU20140109A7/es
Publication of CU24335B1 publication Critical patent/CU24335B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
CUP2014000109A 2012-03-14 2013-03-11 Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer CU24335B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051915 WO2013136254A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds

Publications (2)

Publication Number Publication Date
CU20140109A7 CU20140109A7 (es) 2014-11-27
CU24335B1 true CU24335B1 (es) 2018-04-03

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
CUP2014000109A CU24335B1 (es) 2012-03-14 2013-03-11 Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CUP2014000110A CU24272B1 (es) 2012-03-14 2013-03-11 Derivados de tetrahidropirido-pirimidina como inhibidores de mek

Family Applications After (1)

Application Number Title Priority Date Filing Date
CUP2014000110A CU24272B1 (es) 2012-03-14 2013-03-11 Derivados de tetrahidropirido-pirimidina como inhibidores de mek

Country Status (35)

Country Link
US (5) US9428499B2 (2)
EP (2) EP2834236B1 (2)
JP (3) JP6093384B2 (2)
KR (4) KR102241111B1 (2)
CN (4) CN108383836B (2)
AP (2) AP3859A (2)
AU (4) AU2013234009B2 (2)
BR (1) BR112014022713B1 (2)
CA (2) CA2865167C (2)
CL (2) CL2014002412A1 (2)
CO (2) CO7160029A2 (2)
CR (2) CR20140464A (2)
CU (2) CU24335B1 (2)
DK (2) DK2834236T3 (2)
DO (2) DOP2014000204A (2)
EA (2) EA029768B1 (2)
ES (2) ES2741896T3 (2)
GE (2) GEP201706774B (2)
GT (2) GT201400195A (2)
IL (2) IL234559A (2)
IN (2) IN2014MN01754A (2)
MA (2) MA37405A1 (2)
MX (3) MX355474B (2)
MY (2) MY174188A (2)
NI (2) NI201400107A (2)
NZ (2) NZ629432A (2)
PE (2) PE20141974A1 (2)
PH (2) PH12014502040B1 (2)
PL (1) PL2834237T3 (2)
SG (2) SG11201405006PA (2)
TN (2) TN2014000357A1 (2)
TR (1) TR201811976T4 (2)
UA (2) UA114907C2 (2)
WO (2) WO2013136254A1 (2)
ZA (1) ZA201406186B (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
NZ629432A (en) 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
JP6403172B2 (ja) * 2013-10-25 2018-10-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HRP20230400T1 (hr) 2017-12-21 2023-06-23 Boehringer Ingelheim International Gmbh Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3986408A1 (en) 2019-06-19 2022-04-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022001678A2 (pt) * 2019-07-30 2022-05-03 Edvince Ab Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7808058B2 (ja) * 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022221866A1 (en) * 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023099608A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024542692A (ja) 2021-12-01 2024-11-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
JP2024543976A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
MXPA04005939A (es) * 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
SI1761528T1 (sl) * 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
CA2761108A1 (en) 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
NZ629432A (en) * 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors

Also Published As

Publication number Publication date
AP2014008009A0 (en) 2014-10-31
DK2834237T3 (en) 2018-08-27
UA114906C2 (uk) 2017-08-28
EA028232B1 (ru) 2017-10-31
EP2834237B1 (en) 2018-06-06
JP6431770B2 (ja) 2018-11-28
US9428499B2 (en) 2016-08-30
KR20190073597A (ko) 2019-06-26
IL234560A (en) 2017-06-29
WO2013136254A1 (en) 2013-09-19
AU2018202568A1 (en) 2018-05-10
IN2014MN01755A (2) 2015-07-03
AP3859A (en) 2016-10-31
US20150133424A1 (en) 2015-05-14
NZ629432A (en) 2017-01-27
KR20140138911A (ko) 2014-12-04
CU20140110A7 (es) 2014-11-27
EP2834237A1 (en) 2015-02-11
CN108383836B (zh) 2021-11-12
HK1206020A1 (en) 2015-12-31
CN104271577A (zh) 2015-01-07
MA37400A1 (fr) 2016-05-31
MX2014010925A (es) 2015-04-10
CL2014002411A1 (es) 2015-04-06
US9969731B2 (en) 2018-05-15
US20160331753A1 (en) 2016-11-17
NZ629442A (en) 2016-12-23
PE20141973A1 (es) 2014-12-12
US9827247B2 (en) 2017-11-28
PH12014502041A1 (en) 2014-11-24
PL2834237T3 (pl) 2018-11-30
US20170101408A1 (en) 2017-04-13
DOP2014000203A (es) 2015-02-15
UA114907C2 (uk) 2017-08-28
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
ZA201406186B (en) 2016-06-29
SG11201405007QA (en) 2014-10-30
JP2018115215A (ja) 2018-07-26
JP2015509975A (ja) 2015-04-02
AU2017200493B2 (en) 2018-03-29
SG11201405006PA (en) 2014-10-30
GT201400195A (es) 2017-11-09
CA2865164C (en) 2021-06-08
IN2014MN01754A (2) 2015-07-03
DOP2014000204A (es) 2015-02-15
ES2741896T3 (es) 2020-02-12
MX355474B (es) 2018-04-16
AU2013234009B2 (en) 2016-10-27
KR20190100472A (ko) 2019-08-28
GT201400196A (es) 2017-09-28
MX2014010928A (es) 2015-04-10
AU2017200493A1 (en) 2017-02-16
EP2834236A1 (en) 2015-02-11
TR201811976T4 (tr) 2018-09-21
PE20141974A1 (es) 2014-12-12
CN108383836A (zh) 2018-08-10
NI201400108A (es) 2014-11-28
PH12014502040A1 (en) 2014-11-24
CR20140464A (es) 2014-11-28
BR112014022713A2 (2) 2017-06-20
US9555035B2 (en) 2017-01-31
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
CA2865164A1 (en) 2013-09-19
CA2865167C (en) 2019-08-06
EP2834236B1 (en) 2019-05-22
TN2014000357A1 (en) 2015-12-21
AU2013234009A1 (en) 2014-09-25
EA201491671A1 (ru) 2014-12-30
CO7170131A2 (es) 2015-01-28
NI201400107A (es) 2014-11-26
MX366426B (es) 2019-07-08
CA2865167A1 (en) 2013-09-19
CL2014002412A1 (es) 2015-03-06
GEP201706671B (en) 2017-05-25
MY174188A (en) 2020-03-12
AU2018202568B2 (en) 2019-05-09
JP2015514056A (ja) 2015-05-18
AP2014008008A0 (en) 2014-10-31
BR112014022713B1 (pt) 2021-09-08
AU2013234014B2 (en) 2017-02-02
CU20140109A7 (es) 2014-11-27
WO2013136249A1 (en) 2013-09-19
US20150299186A1 (en) 2015-10-22
MX355526B (es) 2018-04-20
JP6630771B2 (ja) 2020-01-15
AP3834A (en) 2016-09-30
IL234559A (en) 2017-06-29
KR102240101B1 (ko) 2021-04-14
MA37400B1 (fr) 2019-11-29
GEP201706774B (en) 2017-11-27
PH12014502040B1 (en) 2014-11-24
PH12014502041B1 (en) 2014-11-24
US20170112840A1 (en) 2017-04-27
US9573944B2 (en) 2017-02-21
KR102241111B1 (ko) 2021-04-15
DK2834236T3 (da) 2019-08-26
JP6093384B2 (ja) 2017-03-08
ES2684517T3 (es) 2018-10-03
CN107698585A (zh) 2018-02-16
MA37405A1 (fr) 2016-03-31
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
KR20140138910A (ko) 2014-12-04
CN104203947A (zh) 2014-12-10
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
CU24272B1 (es) 2017-08-08

Similar Documents

Publication Publication Date Title
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CR20150045A (es) Inhibidores de hepatitis c
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY35398A (es) Compuestos de biarilamida como inhibidores de cinasa
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
GT201500251A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
MX2016001304A (es) Polimorfo de inhibidores de syk.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
UY33942A (es) Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo